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Purpose: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers. Concurrent 33 
radio-chemotherapy is the standard of care for advanced tumors. However, there is still a need for more efficient 34 
treatments with less secondary effects, resulting from high doses. Therefore, we undertook to explore the 35 
therapeutic potential of ternary combinations- bringing together irradiation, cis-platinum and a TLR3 agonist, 36 
poly(I:C) with aim to reduce dosage of each treatment. This approach is based on our previous studies showing a 37 
selective cytotoxic effect of TLR3 agonists against malignant cells when it is combined with other anti-neoplastic 38 
agents.  39 
Methods: We have explored the cell survival of the head and neck cancer cells (Detroit 562, FaDu, SQ20B and 40 
Cal27) by MTT and caspase 3/7 assay. The radiosensitization effect of poly(I:C) and cisplatin treatment was shown 41 
by western blot, cell cycle analysis, ROS determination and qPCR. 42 
Results: We have shown here that the combination of poly(I:C) and cisplatin can downregulate cIAP2 and survivin 43 
expression, reduce cell survival, induce anti-apoptotic gene expression and apoptosis, generate ROS formation and 44 
cause G2/M phase arrest in HNSCC cell lines.  45 
Conclusions: Our results show that poly(I:C) and cisplatin combination therapy reduces cancer cell survival and 46 
induces radiosensitivity in HNSCC cell lines thus providing a rationale for the development of a novel strategy in 47 
head and neck cancer treatment. 48 
 49 









1. Introduction 57 
 58 
Head and neck squamous cell carcinoma (HNSCC) is the 6th most frequent cancer worldwide [1]. Most 59 
common etiological factors include consumption of tobacco and alcohol and infection with human papilloma virus 60 
(HPV) (for oropharyngeal cancer) [2, 3]. The therapeutic approaches vary depending on the location, stage and 61 
pathohistological properties of the disease, but commonly include surgery, radiotherapy, chemotherapy and 62 
targeted therapy with cetuximab [4]. The combination of radiotherapy and cisplatin-based chemotherapy is the 63 
standard therapeutic approach in the treatment of high-risk locally advanced HNSCC [5]. Cis-platinum brings a 64 
double benefit: it acts as a radio-sensitizer in the tumor volume while it contributes to the control of distant micro-65 
metastases. However, concurrent chemo-radiotherapy is associated with notable toxicity, especially when used in 66 
concurrent setting and in higher doses, which is often necessary for treatment of advanced tumors. Hence the need 67 
for novel therapeutic approaches to increase the therapeutic index. 68 
Toll-like receptors (TLRs) are transmembrane pattern-recognition receptors that are expressed on the 69 
surface of the antigen-presenting cells (APCs), such as dendritic cells (DCs) and macrophages, where they 70 
recognize pathogen-associated molecular patterns, or PAMPs [6, 7]. Once the ligand binds to the receptor, a 71 
signaling cascade is activated, resulting in activation of NF-κB transcription factor, as well as members of the AP-72 
1 and IRF family, finally leading to secretion of interferons, cytokines, and chemokines [8]. TLRs were also found 73 
to be expressed on tumor tissues, including the head and neck cancer [9, 10]. TLR3 is mainly expressed in the 74 
endosome, where it recognizes the double-stranded RNA [11] or polyinosinic:polycytidylic acid (poly(I:C)), a 75 
synthetic dsRNA analog. Several studies reported TLR3 expression in cells of HNSCCs [12, 13].  76 
The influence of TLR3 agonists- especially poly(I:C)- on malignant epithelial cells remains controversial. 77 
Some studies reported the pro-apoptotic effects of TLR3 agonists but these effects were generally obtained using 78 
very high concentrations of agonists which were not compatible with clinical use [14-17]. In contrast, other studies 79 
dealing with low concentrations of agonists showed evidence of their contribution to carcinogenesis and promotion 80 
of tumor growth and invasiveness [18-20]. We have previously shown that these pro-tumorigenic effects result at 81 
least in part from the overexpression of cellular Inhibitor of Apoptosis Protein 2 (c-IAP2). Combining TLR3 82 
agonists with agents inhibiting c-IAP2, not only blocks their pro-tumorigenic effects but also unmasks their strong 83 
pro-apoptotic effects [21, 22]. Because c-IAP2 inhibitors are not yet in clinical use, we investigated whether it was 84 
possible to create the same type of synergy with other anti-neoplastic agents like cis-platinum. 85 
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In our current study we show that the combination of poly(I:C) and cisplatin increases the sensitivity of 86 
malignant cells to irradiation. We further investigated the mechanism underlying this radiosensitization. 87 
 88 
2. Materials and methods 89 
 90 
2.1. Cells and reagents 91 
 92 
Human head and neck cancer cell lines (SQ20B, FaDu and Detroit 562) were maintained in Dulbecco’s 93 
modified Eagle medium (Life technologies, Gaithersburg, USA) supplemented with 2mM L-glutamine, and 10% 94 
fetal calf serum in a humidified chamber at 37ºC in 5% CO2. Detroit 562 cell line was obtained from EACC. The 95 
Fadu and SQ20B lines were provided by Pr Eric Deutsch (Gustave Roussy, Villejuif, France). Poly(I:C) and 96 
polyadenylic–polyuridylic acid (poly(A:U) was obtained from InvivoGen (San Diego, USA). Doxycyclin was 97 
purchased from Sigma Aldrich. Details on RMT5265 have been decribed previously [14]. The compound was 98 
kindly provided by Xiaodong Wang, Dallas. Subclones of SQ20B and FaDu cell lines were established by 99 
transfection with plasmid carrying shRNA directed against TLR3 and inducible by doxycycline (TET-on system) 100 
thus allowing conditional knock-down of TLR3 as described previously [15]. 101 
 102 
2.2. Proliferation assay 103 
 104 
The proliferation experiments were carried out by MTT Cell Proliferation Assay which is a colorimetric 105 
assay system that measures the reduction of a tetrazolium component (MTT) into an insoluble formazan product 106 
by the mitochondria of viable cells. The absorbency (OD, optical density) was measured at 570 nm using a 107 
microplate reader. The absorbency is directly proportional to cell viability. Cells were plated at 1×104 cells/well 108 
in 96-well microtiter plate and treated with poly(I:C) (10 µg/mL), poly(A:U) (10 µg/mL) and cisplatin (1µM) for 109 
45 minutes followed by irradiation. MTT test was performed after 72 hours. Each test point was performed in 110 




2.3. Irradiation 113 
 114 
For gamma irradiation experiments cells were exposed to 60Co γ-irradiation panoramic source (20mGy/s, 115 
Rudjer Boskovic Institute, Radiation Chemistry and Dosimetry Laboratory) to a total of 2.5 Gy or 7.5 Gy.  116 
 117 
2.4. RNA isolation and Real Time PCR 118 
 119 
Cells were treated with poly(I:C) and cisplatin for 45 minutes and irradiated. RNA was isolated after 24 120 
hours with RNeasy Mini Kit (Qiagen, Hilden, Germany) and 0.1 µg of RNA was used as a template for cDNA 121 
synthesis reaction by TaqMan ® Reverse Transcription Reagens Kit (Applied Biosystems, Branchburg, USA). 122 
The PCR reactions were performed with Sybr® Green PCR Master Mix (Applied Biosystems, Warrington, UK) 123 
on a CFX96™ Real-Time PCR Detection System (BioRad, USA). Primer sequences are shown as supplementary 124 
data. Following amplification program was used: 95ºC for 10 min (initial denaturation), 95ºC for 30s 125 
(denaturation), 62ºC for 30s and 60ºC for 30s (annealing and elongation) and we normalized data to 28S rRNA 126 
gene. All data were analyzed using the 2-ΔΔCt (relative quantitation) method, after ensuring that all primer sets 127 
amplified their respective sequence targets with similar efficiencies and without primer-dimers. 128 
 129 
2.5. Measurement of caspase 3/7 enzyme activity 130 
 131 
Caspase 3/7 enzyme activity was determined using the Caspase-Glo 3/7 assay (Promega, Madison, USA) 132 
as previously described [16]. Briefly, SQ20B cells at a concentration of 1.5 ×104 cells/well were plated in a white-133 
walled 96-well plate in 100 μl culture medium and treated with 10 µg/ml poly(I:C) or 1µM cisplatin for 45 minutes, 134 
irradiated and caspase 3/7 activity was determined after 24 hours. 80 μl of Caspase- Glo 3/7 reagent was added on 135 
to each well and the plates were incubated at room temperature for 1 hour. Finally, the luminescence of each 136 




2.6. Western blot analysis 139 
 140 
Cells were seeded in 6 well plates at a density of 0.4x106/well, treated with poly(I:C) and cisplatin for 45 141 
minutes and irradiated. Proteins were isolated after 24 hours by resuspension of the cells in RIPA buffer containing 142 
protease inhibitor cocktail (Complete Mini EDTA-free, Roche.) and the cells were sonicated. 4× Laemmly buffer 143 
(0.25 M Tris-HCl pH 6.8, 20% DTT, 8% Na dodecil sulfate, 40% glicerol, 0.008% bromphenol blue) was added 144 
to obtain 1× mixture and the samples were heated to 95˚C. For Western blot analysis equal amounts of proteins 145 
(40 µg) were separated on 10% or 12% SDS-PAGE and transferred onto 0.2 µm nitrocellulose membrane 146 
(BioRad). The membranes were blocked with 5% nonfat dry milk and were stained with primary antibodies: IAP 147 
Family Antibody Sampler Kit (#9770, Cell Signaling Technology)), PARP (Calbiochem) and actin (Sigma-148 
Aldrich). Afterwards, the membranes were stained with peroxidase conjugated secondary antibody (NA934V, 149 
Amersham, in a concentration 1:3000) and visualized with the chemiluminescent system (Perkin Elmer). 150 
Densitometric calculations of the band intensities corresponding to specific protein were performed using Uvidoc 151 
Cambridge Chemiluminescence Imaging system (Uvitec Cambridge) and UVIband software (Uvitec Cambridge). 152 
 153 
2.7. Measurement of intracellular ROS production 154 
 155 
Cells were seeded at a density of 2×104 cells/well in a 96-well white-walled plate. After washing with 156 
Hanks Balanced Salt Solution (HBSS), cells were incubated for 30 minutes with a nonfluorescent probe for 157 
intracellular ROS detection 2′,7′-dichlorofluorescein diacetate (DCFH-DA, Fluka). This cell-permeable dye 158 
remains non-fluorescent inside the cell until the acetate groups are removed by intracellular esterases and oxidized 159 
by intracellular ROS to the fluorescent compound 2′,7′-dichlorofluorescein (DCF) which can be detected as a 160 
measure for the sensitive and rapid quantitative determination of intracellular ROS in response to oxidative stress. 161 
Following incubation with DCFH-DA, cells were treated with 1µM cisplatin and 10µg/mL of poly(I:C), but in 162 
HBSS instead of culture medium, and after 2 hours, fluorescence intensity was read with Infinite® 200 PRO 163 





2.8. Cell cycle analysis 167 
 168 
Detroit 562 cells were seeded in 12 well dishes and treated with 10 µg/mL of poly(I:C) and 1 µM cisplatin 169 
for 45 minutes and irradiated. After 24 or 72 hours, cells were harvested, washed, fixed in ice-cold 70% ethanol, 170 
treated with RNAse and stained with propidium iodide (Sigma-Aldrich) to evaluate cell cycle distributions. 15.000 171 
events were counted for each experimental setup with routine flow cytometric analysis (FACSCalibur™, Becton-172 
Dickinson, Heidelberg, Germany). Histograms were created and analyzed using ModFit software (Verity Software 173 
House, Topsham, ME, USA). Each experiment was repeated at least three times on different days for validation. 174 
 175 
2.9. Statistics 176 
 177 
Statistical significance was assessed with two-tailed Student’s t test, and results are given as the mean 178 
±SD. 179 
 180 
3. Results 181 
 182 
3.1. Poly(I:C) and cisplatin in combination with irradiation reduce cell survival 183 
 184 
 We have firstly determined that poly(I:C) in combination with cisplatin may increase radiosensitivity in 185 
cancer cells, especially in SQ20B cells which are known to be radioresistant [26]. In Detroit 562 cells poly(I:C) 186 
alone induced cell death up to 90%, which was further increased to 100% when cells were irradiated after the pre-187 
treatment with poly(I:C) (Fig. 1A). poly(I:C) and cisplatin combination pre-treatment showed similar results as 188 
poly(I:C) alone. Poly(I:C) treatment of SQ20B cells reduced cell survival to 30%, which was slightly reduced by 189 
addition of cisplatin. Irradiation of SQ20B cells with 2.5 Gy after poly(I:C) treatment did not show the change, 190 
however, irradiation with 7.5 Gy dose after poly(I:C) pre-treatment showed statistically significant reduction in 191 
cell survival (Fig. 1B). Combinational pre-treatment with poly(I:C) and cisplatin showed statistically significant 192 
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reduction in cell survival only after irradiation with 7.5 Gy in comparison to poly(I:C) pre-treatment alone. All of 193 
the poly(I:C)-related pre-treatments were abolished in shTLR3 cells induced by doxycycline and were statistically 194 
significant in all experiments except in poly(I:C) and cisplatin without the irradiation experiment but even there 195 
the trend is noticeable. This demonstrates that the observed effects are TLR3-dependent. FaDu cells were less 196 
sensitive to 10 µg/mL of poly(I:C) than Detroit 562 and SQ20B with more than 50% of the cell survival after this 197 
treatment (Fig. 1C). Additionally, irradiation did not affect cell survival, even at 7.5 Gy dose.  198 
 199 
3.2. Poly(I:C) and cisplatin downregulate c-IAP2 and reduce cell survival 200 
 201 
   202 
We have firstly showed that poly(I:C) shows similar increase of c-IAP2 expression in Detroit 562 cell 203 
line which is abolished by the addition of cisplatin (Fig. 2A). Other chemotherapeutics, hydroxyurea and 204 
methotrexate, did not show this phenomenon. Cleaved PARP expression was also the highest in samples treated 205 
with poly(I:C) and cisplatin. We have also treated the cells with different concentrations of IAP inhibitor and 206 
showed that even the lowest concentration of IAP inhibitor 10 nM is enough to decrease Detroit 562 cell survival 207 
in combination with 10 µg/mL of poly(I:C) (Fig. 2B). Poly(A:U), which is a more selective TLR3 ligand, did not 208 
induce statistically significant cell death, however, when combining poly(A:U) with higher concentration of IAP 209 
inhibitor (200nM) reduced cell survival for 40%. This means other dsRNA receptors, such as MDA5 and RIG-I 210 
are involved in poly(I:C) cell death induction. Proliferation assay of Detroit 562 cells treated with different 211 
chemotherapeutics, poly(I:C) and IAP inhibitor showed that treatment with cisplatin in combination with poly(I:C) 212 
showed the lowest cell survival which was slightly increased by the addition of IAP inhibitor, suggesting other 213 
anti-apoptotic proteins might be involved (Fig. 2C).  214 
 215 





Since cisplatin and IAP inhibitor showed similar effect in Detroit 562 cells, concerning c-IAP2 expression 219 
and the reduction of cell survival, we sought to further explore this phenomenon in different head and neck cancer 220 
cell lines, especially SQ20B because it is radioresistant. In our subsequent experiment we used cisplatin, as it is 221 
already included into clinical practice. Additionally, since FaDu cells did not show a significant response to 222 
poly(I:C) and cisplatin treatment followed by irradiation, we excluded them from the following experiments. We 223 
first aimed to determine whether poly(I:C) and cisplatin treatment induces pro-apoptotic or anti-apoptotic genes 224 
and whether the gene expression signature is changed after irradiation. BAD, which is a pro-apoptotic gene, is not 225 
significantly over-expressed after poly(I:C) or poly(I:C) and cisplatin treatment. However, poly(I:C) and cisplatin 226 
treatment in combination with irradiation doubles its expression in SQ20B cells. Interestingly, poly(I:C), cisplatin 227 
and irradiation in SQ20B cells in which TLR3 is inhibited increases its expression up to 5 times (Fig. 3A). 228 
Poly(I:C) treatment alone or in combination with cisplatin decreases the expression of another pro-apoptotic gene 229 
PUMA in SQ20B cells. Similar is observed in cells pre-treated with poly(I:C) followed by irradiation. Anti-230 
apoptotic gene survivin expression was increased after poly(I:C) and poly(I:C) and cisplatin treatment and after 231 
poly(I:C) treatment followed by irradiation. In case of poly(I:C) treatment and irradiation, its reduction by TLR3 232 
inhibition was statistically significant. DIABLO, a pro-apoptotic gene, was increased in a statistically significant 233 
manner only after pre-treatment with poly(I:C) followed by irradiation of SQ20B cells. Interestingly, inhibition of 234 
TLR3 in combination with poly(I:C), cisplatin and irradiation increased DIABLO expression to 4 times. However, 235 
irradiation alone increased DIABLO in cells where TLR3 is inhibited so this might be a consequence of irradiation. 236 
We have also tested BAD, BAX and BCL-XL genes but neither of them showed any statistically significant change 237 
(data not shown). Interestingly, in Cal27 cells we have shown different results. PUMA gene was over-expressed 238 
in a statistically significant manner in all cases: after poly(I:C) alone, poly(I:C) and cisplatin, poly(I:C) with 239 
irradiation and poly(I:C) and cisplatin followed by irradiation where, in latter case, its expression was the highest. 240 
The expression of survivin and DIABLO was decreased after poly(I:C) alone with irradiation and cisplatin alone 241 
followed by irradiation treatment (Fig. 3B). In Detroit 562 cells PUMA expression was similar to the one in Cal27 242 
cells. Survivin expression was also downregulated after poly(I:C) stimulation (Fig. 3C). 243 
 244 
3.4. The expression of IAP family proteins after poly(I:C), cisplatin and irradiation treatment 245 
Survivin expression was increased after poly(I:C) stimulation of SQ20B and decreased after the addition 246 
of cisplatin (Fig. 4A), however this was not TLR3 dependent. Detroit 562 cells showed increased expression of 247 
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cIAP2 and survivin after poly(I:C) stimulation which was both abolished by the addition of cisplatin (Fig. 4B). 248 
We have also determined that increased survivin expression in Detroit 562 cells is MEK dependent (Fig. 4C). 249 
 250 
3.5. Poly(I:C) and cisplatin treatment increases apoptosis and ROS formation 251 
 252 
To explore the mechanism of the observed cytotoxic and radiosensitizing effect of poly(I:C) and cisplatin 253 
in radioresistant SQ20B cells, we have measured caspase 3/7 activity and shown that poly(I:C) alone is enough to 254 
increase the caspase 3/7 activity of SQ20B cells for almost two fold and the addition of cisplatin increases the 255 
apoptosis to exactly 200% in comparison to the untreated cells (Fig. 5A). The inhibition of TLR3 reduces the 256 
apoptosis for 40- 60%. However, irradiation did not increase the observed effect thus the results with irradiated 257 
cells were similar to those of non-irradiated cells. We have determined ROS formation after poly(I:C) and cisplatin 258 
treatment to see whether this is the mechanism by which cancer cell lines can become radiosensitive. ROS 259 
formation was increased for 30% after poly(I:C) treatment and poly(I:C) and cisplatin combination showed only 260 
few percent more of ROS formation products (Fig. 5B). Poly(I:C) induced ROS formation was TLR3-dependent 261 
while poly(I:C) and cisplatin combination was not, but this is probably due to increased ROS formation in cisplatin 262 
alone treatment. 263 
 264 
3.6. Poly(I:C) and cisplatin treatment cause G2/M arrest of Detroit 562 cells 265 
 266 
By studying the cells cycle changes after poly(I:C) and cisplatin treatment of Detroit 562 cells we have 267 
established that the combination of poly(I:C) and cisplatin treatment induced G2/M cell arrest (Fig. 6). After 72 268 
hours there were 24% of control cells and 45% of cisplatin and poly(I:C)-treated cells in G2/M phase. This was 269 
further increased by irradiation with 2.5 Gy when 50% of poly(I:C) and cisplatin treated cells were in G2/M phase. 270 
Moreover, after 72 hours there were 25% of untreated cells in S phase and only 15% of poly(I:C) and cisplatin 271 
treated cells. Poly(I:C) alone in combination with irradiation after 24 hours also increased the number of cells in 272 




4. Discussion 275 
 276 
 Poly(I:C) is an interesting candidate for the development of novel therapies against cancer, especially in 277 
combinations with other drugs that may improve the direct apoptotic effects of TLR3 on cancer cells [23]. We 278 
have shown in this study that poly(I:C) in combination with cisplatin might be a reasonable strategy for cancer 279 
treatment as it can, besides synergistically inducing cell death, inhibit the expression of IAP family proteins, 280 
precisely cIAP2 and survivin. This is a pre-clinical evidence based on cell line experiments and should also be 281 
tested in animals for definitive confirmation. 282 
The combined use of TLR3 activation with poly(I:C) and cisplatin in cancer has been previously 283 
investigated. We and the others have shown that poly(I:C) and cisplatin act synergistically to induce cell death 284 
[16, 21, 22]. The results of a very recent study confirmed our hypothesis and showed that pre-treatment with 285 
poly(I:C) increased the amount of cisplatin in the cytoplasm, and greatly increased the low-dose cisplatin-induced 286 
cell death in TLR3- and caspase-3–dependent manner [21].  287 
Nevertheless, we show here another mechanism by which poly(I:C) and cisplatin may reduce cancer cell 288 
survival: by reducing survivin and cIAP2 expression. Survivin belongs to IAP (inhibitor of apoptosis) family which 289 
is known to inhibit apoptosis mainly via inhibition of caspases-3 and -7 [24] and is normally expressed during fetal 290 
development. While survivin is rarely expressed in healthy tissues of adults, it was found to be expressed in 291 
numerous cancers [25, 26], implying its role in tumor development. One study showed that poly(I:C) induced 292 
apoptosis of TLR3-expressing HNSCC cells and that the expression of survivin was down-regulated during 293 
apoptosis [27]. Contrary to that, we have shown here that poly(I:C) induced survivin expression which was reduced 294 
by cisplatin. It might be that the poly(I:C), as it can activate TLR3, MDA5 and RIG-I receptors, has a diverse 295 
function depending on the activated receptor. 296 
We have also tested other pro-apoptotic gene expression after the treatments and irradiation and showed 297 
that their expression is cell-dependent (DIABLO and PUMA). All cell lines investigated here have TP53 mutations, 298 
but SQ20B which has a mild intron mutation with no known effect on the protein level had one pattern of 299 
expression, unlike Detroit 562 and Cal27, which have a non-functional p53 bearing R175H and H193L mutations 300 
respectively (http://p53.iarc.fr/). p53 upregulated modulator of apoptosis (PUMA) gene expression is regulatated 301 
by p53 and it inhibits anti-apoptotic proteins (Mcl-1, Bcl-2, Bcl-XL, Bcl-W and A1) and directly triggers apoptosis 302 
mediated by pro-apoptotic proteins Bax/Bak. It was shown that loss of PUMA alleles is connected with 303 
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radioresistance [28] and since SQ20B cells are radioresistant [29], this might explain the downregulation of PUMA 304 
after poly(I:C) stimulation and generally different pattern of expression compared to Detroit 562 and Cal27 cells. 305 
Cal27 and Detroit 562 show increased PUMA expression. Detroit 562 cells are also more sensitive to irradiation. 306 
Diablo (Smac) is an endogenous inhibitor of IAP proteins [30]. We have shown here that poly(I:C) stimulation of 307 
Detroit 562 cells induced c-IAP2 protein. Additionally, poly(I:C) stimulation downregulated DIABLO while 308 
poly(I:C) and cisplatin treatment abrogated that effect. This might explain c-IAP2 overexpression after poly(I:C) 309 
stimulation and establish once again the similarity in the effect of Smac mimetics and poly(I:C) and cisplatin 310 
combinational treatment. Moreover, the different results in survivin expression in Detroit 562 cells on RNA and 311 
protein level once more demonstrate the importance of protein expression assessment. 312 
Although we have found that apoptosis and ROS formation are increased by poly(I:C) alone and slightly 313 
more after poly(I:C) and cisplatin combination, our cell cycle results show that the combination of poly(I:C) and 314 
cisplatin might be a more potent therapeutic regimen. We have shown that poly(I:C) and cisplatin treatment 315 
induced G2/M cell cycle arrest of Detroit 562 cells after 72 hours. There were 50% more cells in G2/M phase after 316 
the treatment with poly(I:C) and cisplatin than the untreated cells. It is well known that G2/M phase is the most 317 
radiosensitive phase while S phase is the least radiosensitive phase. We have shown that, besides poly(I:C) and 318 
cisplatin induced G2/M arrest, at the same time only 15% of the cells stay in the S phase. This clearly shows that 319 
the combined pre-treatment with poly(I:C) and cisplatin makes the cancer cells sensitive to irradiation. 320 
Radiation therapy also has immunomodulatory effects. On one hand, radiation therapy leads to the 321 
increased Fas expression (a trigger of programmed cell death) and the major histocompatibility complex - MHC 322 
I, which is responsible for antigen presentation to cytotoxic CD8 + lymphocytes [31, 32]. It was also shown that 323 
radiation therapy alone can activate CD8+ lymphocytes through the induction of type I interferons [33]. On the 324 
other hand, through induction of cell death, especially necrosis, radiation may lead to the release of Damage-325 
Associated Molecular Patterns (DAMPs), which also have a dual function. They either may induce immunogenic 326 
tumor cell death or might contribute to cancer cell survival through chronic inflammation and immunosuppression 327 
[34]. The idea of combining the activation of TLR3 ligands and radiation therapy is based on the premise that 328 
TLR3 activation may induce apoptosis of cancer cells and irradiation can stimulate the immune system response 329 
in addition to inducing cancer cell death through DNA breaks. For TLR9 and TLR7 agonists, studies have already 330 
shown the benefits of their combination with radiotherapy [35-37]. Kang et al have demonstrated that activation 331 
of TLR3 and -7 enhanced autophagy-induced cell death in radiotherapy of breast cancer [38]. Additionally, there 332 
are currently two ongoing clinical trials phase I and I/II which are investigating the potential co-administration of 333 
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poly ICLC with radiotherapy in patients with lymphoma (NCT02061449, NCT01976585) [10]. Moreover, aside 334 
from radiation therapy-induced direct tumor cell death and enhanced tumor specific immunity, it has been observed 335 
that irradiation may upregulate programmed death-ligand 1 (PD-L1). The PD-L1/PD-1 axis has been characterized 336 
as a potent inhibitor of immune activation through inhibition of effector T cell function. Therefore, an approach to 337 
combine radiotherapy with antibodies against PD1/PDL1 axis is another strategy for head and neck cancer therapy 338 
[39, 40]. Additionally, another publication also showed that combination of poly(I:C) with PD-L1 mAb inhibited 339 
tumor development in several mouse models of cancer. This combinatorial therapy also induced a long-lasting 340 
protection against tumor re-challenges [41]. Also, Takeda et al showed in a very recent paper that a TLR3 specific 341 
ligand ARNAX, which elicits less cytokine production than poly(I:C), in combination with anti-PD-L1 Ab and 342 
tumor antigen may overcome PD-1 blockade unresponsiveness and lead to tumor regression without inflammation 343 
[42]. Therefore, the utilization of TLR3 agonist in combination with radiotherapy or PD1/PD-L1 inhibitors may 344 
induce multiple beneficial effects during cancer treatment. 345 
To conclude, the data presented in this paper suggest that the use of poly(I:C), cisplatin and radiotherapy 346 
could be the right strategy for head and neck cancer treatment. The main evidence, besides reduced cell survival, 347 
includes reduced survivin and c-IAP expression, increased PUMA and DIABLO gene expression (depending on 348 
the cell lines used), increased ROS and increased G2/M cell cycle arrest. 349 
 350 
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Figure legends 481 
Fig. 1 The survival of head and neck cancer cell lines after the treatment with poly(I:C) (10 µg/mL), poly(A:U) 482 
(10 µg/mL) and cisplatin (1µM) for 45 minutes followed by irradiation: Detroit 562 (a), SQ20B (b) and FaDu (c) 483 
cells. pIC- poly(I:C), pAU- poly(A:U), cisPt- cisplatin, sh control+dox- cells transfected with control plasmid and 484 
induced by doxycyline, shTLR3 dox- cells transfected with TLR3 plasmid and induced by doxycycline. *p<0.05, 485 
**p<0.01, ***p<0.005, ****p<0.001 486 
Fig. 2 The effect of poly(I:C), poly(A:U), chemotherapeutics and cIAP inhibitor RMT on Detroit 562 cells. (a) 487 
The expression of cIAP2 (70kDa) and PARP (89/116 kDa) after the treatment with poly(I:C) (1 or 10 µg/mL) and 488 
chemotherapeutics (HU- 500 µM, MTX- 5µM, cisPt- 5µM). (b) Cell survival after the treatment with poly(I:C), 489 
poly(A:U) and RMT 5625. (c) Cell survival after the treatment with poly(I:C), poly(A:U), RMT 5625 (10nM) and 490 
chemotherapeutics. pIC- poly(I:C), pAU- poly(A:U), HU- hydroxyurea, MTX- methotrexate, cisPt- cisplatin, 491 
DMSO- dimethyl sulfoxide. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 492 
Fig. 3 The expression of pro- and anti-apoptotic genes after the treatment of head and neck cancer cells. (a) SQ20B 493 
cells treated with poly(I:C) (10 µg/mL) and cisplatin (1µM) followed by irradiation. shC- cells trasfected with 494 
control plasmid, shTLR3- cells transfected with TLR3 plasmid. (b) Cal27 cells treated with poly(I:C) and cisplatin 495 
followed by irradiation. (c) Detroit 562 cells treated with poly(I:C) and cisplatin followed by irradiation. pIC- 496 
poly(I:C), cis- cisplatin. *p<0.05, **p<0.01 497 
Fig. 4 The expression of survivin and cIAP2 in: (a) SQ20B cells after poly(I:C) (10 µg/mL) and cisplatin (1µM) 498 
treatment followed by irradiation. (b) Detroit 562 cels after poly(I:C) and cisplatin treatment followed by 499 
irradiation. (c) Detroit 562 cells pre-treated with HIF, Myc and MEK inhibitors, treated with poly(I:C) and cisplatin 500 
followed by irradiation. pIC- poly(I:C), cisPt- cisplatin, HIF-HIF inhibitor, Myc-Myc inhibitor, MEK- MEK 501 
inhibitor. Loading control- membrane dyed with amido black and scanned. 502 
Fig. 5 The effect of poly(I:C) (10 µg/mL) and cisplatin (1µM) treatment on SQ20B cells apoptosis induction (a) 503 
and ROS formation (b). shcontrol- cells trasfected with control plasmid, shTLR3- cells transfected with TLR3 504 
plasmid, pIC- poly(I:C), cisPt- cisplatin. *p<0.05 505 
Fig. 6 Cell cycle analysis. Histograms present cell cycle distribution of Detroit 562 cells after poly(I:C) (10 µg/mL) 506 
and cisplatin (1µM) treatment for 24h (a) and 72h (b) followed by irradiation (c and d). (e) The flow cytometric 507 
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histograms are representative of 3 separate experiments and the statistical analysis of each cell cycle phase arrest 508 
is presented in section e. *p<0.05 509 
 510 
